Placebo to BAY 3401016, BAY 3401016
22419
Phase 2 small_molecule active
Quick answer
Placebo to BAY 3401016, BAY 3401016 for Alport Syndrome, Chronic kidney disease is a Phase 2 program (small_molecule) at Bayer AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer AG
- Indication
- Alport Syndrome, Chronic kidney disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active